Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AC Immune logo — Shifting the treatment paradigm for neurodegenerative diseas...

AC Immune

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention.

Founded 2003 Switzerland Lausanne, Switzerland 179 employees Post-IPO Equity Total: $169.15M Biotechnology, Health and Wellness +1

General Information

Company Name AC Immune
Founded Year 2003
Location Switzerland Lausanne, Switzerland
Employees 179
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with AC Immune. To contact AC Immune, visit acimmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AC Immune compare?

A PDF of AC Immune and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AC Immune soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AC Immune

AC Immune, a clinical-stage biopharmaceutical company, is focused on becoming a global leader in precision medicine for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company's pioneering science is anchored by its two clinically validated technology platforms, SupraAntigen™ and Morphomer™, which fuel a diverse pipeline of nine therapeutic and three diagnostic candidates, with six currently in clinical trials. AC Immune's strong track record of securing strategic partnerships with leading global pharmaceutical companies, including Genentech, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., has resulted in substantial non-dilutive funding and potential milestone payments exceeding $3 billion. In 2023, AC Immune secured a significant $50.05M Post-IPO Equity investment, attracting prominent investors such as Redmile Group, BVF Partners, StemPoint Capital, and Avidity Partners. The company's commitment to breakthrough therapies and strategic partnerships positions it for further growth and innovation in the field of neurodegenerative diseases, emphasizing its potential as an attractive investment opportunity in the biotechnology and pharmaceutical industries. With its headquarters in Switzerland and a compelling portfolio of assets, AC Immune presents a compelling case for venture capital consideration.

Business keywords: neurodegeneration, precision medicine, biopharmaceutical, therapies, clinical-stage, Alzheimer's disease, Parkinson's disease, misfolded proteins, technology platforms, clinical trials, strategic partnerships, pharmaceutical companies, diagnostic candidates, biotech

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $50.05M 4
Redmile Group StemPoint Capital
Redmile Group, StemPoint Capital +2
15 Dec 2023
Series E $43.50M 1
Dietmar Hopp
09 May 2016
Series D Fr.20.00M 1
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding
09 Jan 2014
Series C $34.60M -
28 Jan 2009
Series B Fr.21.00M -
12 May 2005

AC Immune Alternatives & Competitors

View All Alternatives
AC Immune vs
AFFiRiS AG
AFFiRiS AG Austria

Novel disease-modifying therapies for neurodegenerative diseases. From brains for brains. From us fo...

2 employees
Biotechnology, Pharmaceutical
Compare AC Immune vs AFFiRiS AG
AC Immune vs
CaSRevolution
CaSRevolution Italy

A new hope for patients affected by Alzheimer’s disease

Seed
6 employees
Biotechnology, Health Care
AC Immune vs
Acadia Pharmaceuticals
Acadia Pharmaceuticals United States

Acadia is trailblazing breakthroughs in neuroscience to elevate life.

Post-IPO Equity
1028 employees
Biotechnology, Health Care
View all alternatives

FAQ About AC Immune

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention.
AC Immune was founded in 2003.
AC Immune is headquartered in Lausanne, Switzerland.
AC Immune operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on neurodegeneration, precision medicine, biopharmaceutical and therapies.
AC Immune has approximately 179 employees.
AC Immune has completed 5 funding rounds, raising a total of $169.15M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to AC Immune include AFFiRiS AG, CaSRevolution, Acadia Pharmaceuticals, APRINOIA Therapeutics, Zavante Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AC Immune and AFFiRiS AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AC Immune, https://bouncewatch.com/company/ac-immune, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes